The Liver Meeting, The 62nd Annual Meeting of the American Association for the Study of Liver Diseases

November 4-8, 2011 - San Francisco

AASLD 2011: Milk Thistle Extract Did Not Improve Liver Inflammation or Quality of Life for Hepatitis C Patients

Oral silymarin, an extract from the milk thistle plant, was well-tolerated but did not reduce alanine aminotransferase (ALT) or HCV RNA levels or improve quality of life for hepatitis C patients who did not respond to interferon, researchers reported at the 62nd Annual Meeting of the American Association for the Study of Liver Disease (AASLD 2011) last month in San Francisco. alt

Read more:

AASLD 2011: Daclatasvir with Pegylated Interferon/ Ribavirin Produces High Rates of HCV Suppression

Most treatment-naive chronic hepatitis C patients who added the experimental HCV NS5A inhibitor daclatasvir (BMS-790052) to pegylated interferon/ribavirin achieved undetectable viral load at 12 and 24 weeks, according to data presented at the at the 62nd Annual Meeting of the American Association for the Study of Liver Disease (AASLD 2011) last month in San Francisco.alt

Read more:

AASLD 2011: Upping Entecavir Dose Does Not Improve Hepatitis B Treatment Response

Doubling the usual dose of entecavir (Baraclude) did not increase its effectiveness for treating chronic hepatitis B, according to a study presented at the 62nd Annual Meeting of the American Association for the Study of Liver Disease (AASLD 2011) this month in San Francisco.alt

Read more:

AASLD 2011: All-Oral Combination of BI 201335, BI 207127 and Ribavirin Shows Good Efficacy at 12 Weeks

An interferon-free triple regimen containing the hepatitis C virus (HCV) protease inhibitor BI 201335, the HCV polymerase inhibitor BI 207127, and ribavirin for 12 weeks suppressed viral load in three-quarters of previously untreated genotype 1 patients, according to findings from the SOUND-C trials presented at the American Association for the Study of Liver Diseases Liver Meeting (AASLD 2011) in San Francisco.alt

Read more:

AASLD 2011: Predictors of Response to Boceprevir plus Pegylated Interferon/Ribavirin

Low baseline viral load, hepatitis C virus (HCV) subtype 1b, and absent or mild liver damage predicted sustained response to treatment with boceprevir (Victrelis) plus pegylated interferon/ribavirin, researchers report at the American Association for the Study of Liver Diseases Liver Meeting (AASLD 2011) this month in San Francisco.alt

Read more: